8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Feb 11, 2026·SEC
Material company update
Feb 4, 2026·SEC
Bio-Techne Corporation(TECH)Earnings, Financials & Key Ratios
TECH•NASDAQ
126.0× P/E·Price updated Jun 19, 2026
AboutBio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.Show more
- Revenue$1.22B+5.2%
- EBITDA$212M-33.4%
- Net Income$73M-56.3%
- EPS (Diluted)0.46-56.2%
- Gross Margin64.8%-2.4%
- EBITDA Margin17.4%-36.7%
- Operating Margin8.38%-53.0%
- Net Margin6.02%-58.5%
- ROE3.68%-55.8%
TECH Key Insights
Bio-Techne Corporation (TECH) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓FCF machine: 21.0% free cash flow margin
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 10.5%
- ✓Healthy 5Y average net margin of 17.1%
✗Weaknesses
- ✗Profits declining 20.4% over 5 years
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when TECH posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TECH Price & Volume
Bio-Techne Corporation (TECH) stock price & volume — 10-year historical chart
Loading chart...
TECH Growth Metrics
Bio-Techne Corporation (TECH) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years10.43%
5 Years10.55%
3 Years3.33%
TTM0.17%
Profit CAGR
10 Years-3.76%
5 Years-20.37%
3 Years-35.38%
TTM-16.78%
EPS CAGR
10 Years-4.38%
5 Years-20.52%
3 Years-34.8%
TTM-15.85%
Return on Capital
10 Years10.05%
5 Years10.21%
3 Years8.42%
Last Year4.15%
TECH Recent Earnings
Bio-Techne Corporation (TECH) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 3/12 qtrs (25%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$0.53-3.6%
$0.55
Rev
$311M-1.5%
$316M
Q1 2026
Feb 4, 2026Metric
Actual
Est
EPS
$0.46+7.0%
$0.43
Rev
$296M+1.9%
$290M
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.42-0.3%
$0.42
Rev
$287M-1.6%
$291M
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$0.53+6.1%
$0.50
Rev
$317M+7.6%
$295M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.53vs $0.55-3.6% | $311Mvs $316M-1.5% |
| Q1 2026 | Feb 4, 2026 | $0.46vs $0.43+7.0% | $296Mvs $290M+1.9% |
| Q4 2025 | Nov 5, 2025 | $0.42vs $0.42-0.3% | $287Mvs $291M-1.6% |
| Q3 2025 | Aug 6, 2025 | $0.53vs $0.50+6.1% | $317Mvs $295M+7.6% |
Based on last 12 quarters of dataView full earnings history →
TECH Peer Comparison
Bio-Techne Corporation (TECH) competitors in Life Science Tools and Reagents — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RGEN | 7.45B | 132.02 | 153.51 | 16.36% | 6.73% | 2.46% | 0.33 | |
 NEOG | 2.03B | 9.31 | -1.85 | -3.2% | -68.47% | -28.64% | 0.44 | |
 AZTA | 1.07B | 23.31 | -19.11 | 3.55% | -29.86% | -10.69% | 0.06 | |
 RVTY | 11.18B | 100.00 | 48.08 | 3.67% | 8.3% | 3.28% | 0.48 | |
 MESO | 1.85B | 14.37 | -17.11 | 191.39% | -5.94% | -17.1% | 0.21 | |
 TMO | 172.66B | 464.61 | 26.19 | 3.91% | 15.18% | 13.23% | 0.76 | |
 DHR | 125.4B | 177.17 | 35.15 | 2.9% | 14.89% | 7.06% | 0.35 | |
 ILMN | 24.6B | 161.93 | 29.71 | -0.78% | 19.43% | 32.84% | 0.94 |
Compare TECH vs Peers
Bio-Techne Corporation (TECH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TECH Income Statement
Bio-Techne Corporation (TECH) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 563M | 642.99M | 714.01M | 738.69M | 931.03M | 1.11B | 1.14B | 1.16B | 1.22B | 1.21B |
Revenue Growth % | 12.82% | 14.21% | 11.04% | 3.46% | 26.04% | 18.75% | 2.81% | 1.97% | 5.23% | 0.17% |
Cost of Goods Sold | 188.46M | 210.85M | 240.51M | 255.5M | 298.18M | 349.1M | 366.89M | 389.33M | 429.36M | 424.32M |
COGS % of Revenue | 33.47% | 32.79% | 33.69% | 34.59% | 32.03% | 31.58% | 32.28% | 33.59% | 35.2% | - |
Gross Profit | 374.54M▲ 0% | 432.14M▲ 15.4% | 473.49M▲ 9.6% | 483.19M▲ 2.0% | 632.85M▲ 31.0% | 756.5M▲ 19.5% | 769.82M▲ 1.8% | 769.73M▼ 0.0% | 790.27M▲ 2.7% | 786.49M▲ 0% |
Gross Margin % | 66.53% | 67.21% | 66.31% | 65.41% | 67.97% | 68.42% | 67.72% | 66.41% | 64.8% | 64.96% |
Gross Profit Growth % | 11.25% | 15.38% | 9.57% | 2.05% | 30.97% | 19.54% | 1.76% | -0.01% | 2.67% | - |
Operating Expenses | 252.76M | 295.96M | 326.77M | 325.77M | 395.55M | 459.91M | 470.87M | 563.04M | 688.02M | 632.74M |
OpEx % of Revenue | 44.89% | 46.03% | 45.77% | 44.1% | 42.49% | 41.6% | 41.42% | 48.58% | 56.41% | - |
Selling, General & Admin | 199.24M | 240.64M | 264.36M | 240.88M | 289.92M | 339M | 352.44M | 393.32M | 415.1M | 362.46M |
SG&A % of Revenue | 35.39% | 37.42% | 37.02% | 32.61% | 31.14% | 30.66% | 31.01% | 33.93% | 34.03% | - |
Research & Development | 53.51M | 55.33M | 62.41M | 65.19M | 70.6M | 87.14M | 92.49M | 96.66M | 99.5M | 96.85M |
R&D % of Revenue | 9.51% | 8.6% | 8.74% | 8.83% | 7.58% | 7.88% | 8.14% | 8.34% | 8.16% | - |
Other Operating Expenses | 0 | 0 | 0 | 19.7M | 35.03M | 33.77M | 25.94M | 73.06M | 173.42M | 1000K |
Operating Income | 121.78M▲ 0% | 136.18M▲ 11.8% | 125.58M▼ 7.8% | 157.42M▲ 25.4% | 237.3M▲ 50.7% | 296.59M▲ 25.0% | 298.94M▲ 0.8% | 206.69M▼ 30.9% | 102.25M▼ 50.5% | 153.75M▲ 0% |
Operating Margin % | 21.63% | 21.18% | 17.59% | 21.31% | 25.49% | 26.83% | 26.3% | 17.83% | 8.38% | 12.7% |
Operating Income Growth % | -19.13% | 11.82% | -7.78% | 25.35% | 50.74% | 24.99% | 0.79% | -30.86% | -50.53% | - |
EBITDA | 181.82M | 200.64M | 203.75M | 240.16M | 325.04M | 397.66M | 406.18M | 318.4M | 212.16M | 254.08M |
EBITDA Margin % | 32.29% | 31.2% | 28.54% | 32.51% | 34.91% | 35.97% | 35.73% | 27.47% | 17.4% | 20.98% |
EBITDA Growth % | -5.97% | 10.35% | 1.55% | 17.87% | 35.35% | 22.34% | 2.14% | -21.61% | -33.37% | -10.15% |
D&A (Non-Cash Add-back) | 60.04M | 64.46M | 78.17M | 82.74M | 87.75M | 101.07M | 107.24M | 111.71M | 109.9M | 100.33M |
EBIT | 119.32M | 136.14M | 133.72M | 295.67M | 162.13M | 312.69M | 349.87M | 201.43M | 106.97M | 158.69M |
Net Interest Income | -7.06M | -9.78M | -21.14M | -18.59M | -13.48M | -10.52M | -7.8M | -12.41M | -4.62M | -7.07M |
Interest Income | 304K | 409K | 569K | 605K | 473K | 794K | 3.41M | 3.32M | 3.89M | 3.43M |
Interest Expense | 7.36M | 10.19M | 21.7M | 19.2M | 13.95M | 11.31M | 11.21M | 15.74M | 8.51M | 10.51M |
Other Income/Expense | -8.62M | -10.23M | -34.7M | 119.06M | -89.12M | 4.8M | 39.72M | -21M | -3.79M | -6.61M |
Pretax Income | 113.16M▲ 0% | 125.95M▲ 11.3% | 112.02M▼ 11.1% | 276.48M▲ 146.8% | 148.18M▼ 46.4% | 301.39M▲ 103.4% | 338.66M▲ 12.4% | 185.69M▼ 45.2% | 98.46M▼ 47.0% | 147.14M▲ 0% |
Pretax Margin % | 20.1% | 19.59% | 15.69% | 37.43% | 15.92% | 27.26% | 29.79% | 16.02% | 8.07% | 12.15% |
Income Tax | 35.88M | -602K | 15.94M | 47.18M | 8.59M | 38.29M | 53.22M | 17.58M | 25.06M | 37.58M |
Effective Tax Rate % | 31.7% | -0.48% | 14.23% | 17.07% | 5.8% | 12.7% | 15.71% | 9.47% | 25.45% | 25.54% |
Net Income | 77.29M▲ 0% | 125.35M▲ 62.2% | 96.07M▼ 23.4% | 229.3M▲ 138.7% | 140.41M▼ 38.8% | 272.05M▲ 93.8% | 285.26M▲ 4.9% | 168.1M▼ 41.1% | 73.4M▼ 56.3% | 109.57M▲ 0% |
Net Margin % | 13.73% | 19.49% | 13.46% | 31.04% | 15.08% | 24.61% | 25.1% | 14.5% | 6.02% | 9.05% |
Net Income Growth % | -26.03% | 62.19% | -23.36% | 138.67% | -38.76% | 93.75% | 4.86% | -41.07% | -56.34% | -16.78% |
Net Income (Continuing) | 76.09M | 126.15M | 96.07M | 229.3M | 139.59M | 263.1M | 285.44M | 168.1M | 73.4M | 109.56M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 8.26M | -759K | 0 | 0 | 0 | 0 |
EPS (Diluted) | 0.52▲ 0% | 0.82▲ 57.7% | 0.62▼ 24.4% | 1.45▲ 133.9% | 0.87▼ 40.0% | 1.66▲ 90.8% | 1.76▲ 6.0% | 1.05▼ 40.3% | 0.46▼ 56.2% | 0.70▲ 0% |
EPS Growth % | -25.71% | 57.69% | -24.39% | 133.87% | -40% | 90.8% | 6.02% | -40.34% | -56.19% | -15.85% |
EPS (Basic) | 0.52 | 0.84 | 0.64 | 1.50 | 0.91 | 1.73 | 1.81 | 1.07 | 0.47 | - |
Diluted Shares Outstanding | 150M | 152.22M | 155.57M | 157.6M | 161.93M | 164.12M | 161.85M | 160.77M | 159.72M | 156.94M |
Basic Shares Outstanding | 149.25M | 149.9M | 151.12M | 152.8M | 154.99M | 156.88M | 157.18M | 157.71M | 157.52M | 155.89M |
Dividend Payout Ratio | 61.23% | 38.27% | 50.34% | 21.33% | 35.34% | 18.45% | 17.63% | 29.99% | 68.65% | - |
TECH Balance Sheet
Bio-Techne Corporation (TECH) balance sheet — assets, liabilities & shareholders' equity
| Metric | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 345.26M | 398.37M | 412.61M | 520.92M | 510.61M | 605.56M | 621.48M | 617.42M | 608.3M | 688.05M |
Cash & Short-Term Investments | 157.71M | 181.75M | 166.03M | 270.89M | 231.55M | 247.03M | 204.31M | 152.86M | 162.19M | 209.82M |
Cash Only | 91.61M | 121.99M | 100.89M | 146.63M | 199.09M | 172.57M | 180.57M | 151.79M | 162.19M | 209.82M |
Short-Term Investments | 66.1M | 59.76M | 65.15M | 124.27M | 32.46M | 74.46M | 23.74M | 1.07M | 0 | 0 |
Accounts Receivable | 116.83M | 120.3M | 137.47M | 122.53M | 145.38M | 194.55M | 218.47M | 241.39M | 206.88M | 217.92M |
Days Sales Outstanding | 75.74 | 68.29 | 70.27 | 60.55 | 57 | 64.23 | 70.15 | 76.02 | 61.91 | 59.79 |
Inventory | 60.15M | 85.65M | 91.05M | 103.15M | 116.75M | 141.12M | 171.64M | 179.73M | 189.45M | 201.18M |
Days Inventory Outstanding | 116.5 | 148.26 | 138.18 | 147.36 | 142.91 | 147.55 | 170.76 | 168.5 | 161.05 | 171.88 |
Other Current Assets | 13.33M | 10.67M | 18.06M | 24.34M | 16.92M | 22.86M | 27.07M | 43.43M | 49.79M | 59.14M |
Total Non-Current Assets | 1.21B | 1.19B | 1.47B | 1.51B | 1.75B | 1.69B | 2.02B | 2.09B | 1.95B | 1.86B |
Property, Plant & Equipment | 135.12M | 145.35M | 154.04M | 248.29M | 281.74M | 288.8M | 324.53M | 342.44M | 319.12M | 301.31M |
Fixed Asset Turnover | 4.17x | 4.42x | 4.64x | 2.98x | 3.30x | 3.83x | 3.50x | 3.38x | 3.82x | 3.92x |
Goodwill | 579.03M | 597.89M | 732.67M | 728.31M | 843.07M | 822.1M | 872.74M | 972.66M | 980.93M | 977.8M |
Intangible Assets | 452.04M | 446.33M | 579.43M | 516.54M | 615.97M | 531.52M | 534.64M | 507.08M | 365.6M | 319.07M |
Long-Term Investments | 40.38M | 2.66M | -89.75M | 0 | 0 | 0 | 255.86M | 242.34M | 250.98M | 1.02B |
Other Non-Current Assets | -116.98M | -83.69M | 5.67M | 13.52M | 11.3M | 46.83M | 29.45M | 21.93M | 22.63M | 10.22M |
Total Assets | 1.56B▲ 0% | 1.59B▲ 2.3% | 1.88B▲ 18.3% | 2.03B▲ 7.6% | 2.26B▲ 11.6% | 2.29B▲ 1.4% | 2.64B▲ 15.0% | 2.7B▲ 2.5% | 2.56B▼ 5.4% | 2.55B▲ 0% |
Asset Turnover | 0.36x | 0.40x | 0.38x | 0.36x | 0.41x | 0.48x | 0.43x | 0.43x | 0.48x | 0.48x |
Asset Growth % | 37.82% | 2.35% | 18.28% | 7.6% | 11.61% | 1.41% | 14.99% | 2.47% | -5.4% | -22.14% |
Total Current Liabilities | 135.36M | 78.69M | 101.98M | 106.67M | 152.28M | 176.02M | 128.51M | 159.38M | 175.85M | 153.28M |
Accounts Payable | 16.86M | 18.45M | 16.21M | 23.09M | 29.38M | 33.87M | 25.68M | 37.97M | 25.31M | 23.49M |
Days Payables Outstanding | 32.65 | 31.94 | 24.6 | 32.99 | 35.97 | 35.41 | 25.55 | 35.59 | 21.52 | 22.63 |
Short-Term Debt | 0 | 0 | 12.5M | 12.5M | 12.5M | 12.5M | 0 | 0 | 0 | 14.18M |
Deferred Revenue (Current) | 5.97M | 7.07M | 9.08M | 13.05M | 19M | 23.41M | 23.07M | 27.93M | 32.57M | 132.48M |
Other Current Liabilities | 65.1M | 21.4M | 3.4M | 0 | 3.89M | 1.24M | 1.41M | 2.15M | 1.65M | 19.77M |
Current Ratio | 2.55x | 5.06x | 4.05x | 4.88x | 3.35x | 3.44x | 4.84x | 3.87x | 3.46x | 4.49x |
Quick Ratio | 2.11x | 3.97x | 3.15x | 3.92x | 2.59x | 2.64x | 3.50x | 2.75x | 2.38x | 3.18x |
Cash Conversion Cycle | 159.59 | 184.61 | 183.85 | 174.92 | 163.94 | 176.37 | 215.36 | 208.92 | 201.44 | 209.04 |
Total Non-Current Liabilities | 470.47M | 435.37M | 616.84M | 539.73M | 539.44M | 417.78M | 543.67M | 475.64M | 463.21M | 312.02M |
Long-Term Debt | 343.77M | 339M | 492.66M | 344.24M | 328.83M | 243.41M | 350M | 319M | 346M | 200M |
Capital Lease Obligations | 0 | 0 | 0 | 67.25M | 67.63M | 58.13M | 93.77M | 87.62M | 83.96M | 317.99M |
Deferred Tax Liabilities | 118M | 86.29M | 89.75M | 101.09M | 93.13M | 98.99M | 88.98M | 55.86M | 6.17M | 42.67M |
Other Non-Current Liabilities | 129.3M | 9.34M | 33.11M | 27.15M | 49.86M | 17.24M | 10.92M | 13.16M | 27.08M | 19.4M |
Total Liabilities | 605.83M | 514.06M | 718.82M | 646.4M | 691.72M | 593.79M | 672.18M | 635.02M | 639.06M | 465.3M |
Total Debt | 349.9M | 339M | 505.16M | 433.53M | 420.55M | 325.97M | 454.96M | 419.54M | 444.06M | 290.32M |
Net Debt | 258.29M | 217.01M | 404.27M | 286.9M | 221.46M | 153.4M | 274.39M | 267.75M | 281.87M | 80.5M |
Debt / Equity | 0.37x | 0.31x | 0.43x | 0.31x | 0.27x | 0.19x | 0.23x | 0.20x | 0.23x | 0.14x |
Debt / EBITDA | 1.92x | 1.69x | 2.48x | 1.81x | 1.29x | 0.82x | 1.12x | 1.32x | 2.09x | 1.14x |
Net Debt / EBITDA | 1.42x | 1.08x | 1.98x | 1.19x | 0.68x | 0.39x | 0.68x | 0.84x | 1.33x | 0.32x |
Interest Coverage | 16.21x | 13.36x | 6.16x | 15.40x | 11.62x | 27.65x | 31.20x | 12.80x | 12.57x | 15.11x |
Total Equity | 950.83M▲ 0% | 1.08B▲ 13.5% | 1.17B▲ 8.0% | 1.38B▲ 18.5% | 1.57B▲ 13.8% | 1.7B▲ 8.3% | 1.97B▲ 15.6% | 2.07B▲ 5.2% | 1.92B▼ 7.3% | 2.09B▲ 0% |
Equity Growth % | 8.14% | 13.5% | 8.01% | 18.5% | 13.76% | 8.26% | 15.61% | 5.2% | -7.25% | -15.25% |
Book Value per Share | 6.34 | 7.09 | 7.49 | 8.76 | 9.70 | 10.36 | 12.15 | 12.87 | 12.01 | 13.29 |
Total Shareholders' Equity | 950.83M | 1.08B | 1.17B | 1.38B | 1.56B | 1.7B | 1.97B | 2.07B | 1.92B | 2.09B |
Common Stock | 374K | 376K | 379K | 385K | 390K | 1.57M | 1.58M | 1.58M | 1.55M | 1.56M |
Retained Earnings | 799.03M | 876.93M | 931.93M | 1.06B | 1.09B | 1.12B | 1.31B | 1.33B | 1.07B | 1.15B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -48.94M | -44.81M | -83.52M | -97.2M | -57.29M | -75.2M | -66.06M | -78.32M | -59.88M | -66.86M |
Minority Interest | 0 | 0 | 0 | 0 | 8.26M | -759K | 0 | 0 | 0 | 0 |
TECH Cash Flow Statement
Bio-Techne Corporation (TECH) cash flow — operating, investing & free cash flow history
| Metric | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 143.45M | 170.37M | 181.62M | 205.22M | 352.16M | 325.27M | 254.39M | 298.98M | 287.56M | 294.86M |
Operating CF Margin % | 25.48% | 26.5% | 25.44% | 27.78% | 37.83% | 29.42% | 22.38% | 25.8% | 23.58% | - |
Operating CF Growth % | -0.29% | 18.77% | 6.6% | 12.99% | 71.61% | -7.64% | -21.79% | 17.53% | -3.82% | 81.71% |
Net Income | 76.09M | 126.15M | 96.07M | 229.3M | 139.59M | 263.1M | 285.44M | 168.07M | 73.4M | 109.57M |
Depreciation & Amortization | 60.04M | 64.46M | 78.17M | 82.74M | 87.75M | 101.07M | 107.24M | 111.71M | 109.9M | 100.33M |
Stock-Based Compensation | 14.63M | 28.24M | 32.28M | 32.37M | 48.98M | 42.18M | 39.23M | 38.04M | 40.83M | 40.69M |
Deferred Taxes | -3.43M | -46.72M | -13.58M | 13.13M | -27.43M | 6.82M | -29.57M | -39.45M | -51.11M | -24.24M |
Other Non-Cash Items | 10.06M | -3.67M | 16.43M | -147.07M | 74.02M | -18.38M | -57.37M | 30.71M | 102.99M | 51.07M |
Working Capital Changes | -13.93M | 1.9M | -27.75M | -5.25M | 29.26M | -69.52M | -90.58M | -10.11M | 11.54M | 17.45M |
Change in Receivables | -19.69M | -308.66M | -2.7M | 6.56M | -15.55M | -57.6M | -23.36M | -31.13M | 42.6M | 13.99M |
Change in Inventory | -732K | -13.33M | -13.65M | -14.86M | -7.14M | -32.01M | -30.17M | -14.21M | -18.14M | -3.17M |
Change in Payables | 5.7M | 5.03M | 6.1M | 10.34M | 19.09M | 12.74M | -7.91M | 25.77M | -13.95M | -8.16M |
Cash from Investing | -305.95M | -38.71M | -336.8M | 27.09M | -243.52M | -96.85M | -265.65M | -203.03M | -35.18M | -10.73M |
Capital Expenditures | -15.18M | -20.93M | -25.41M | -51.74M | -44.3M | -44.91M | -38.24M | -62.88M | -31.01M | -25.26M |
CapEx % of Revenue | 2.7% | 3.26% | 3.56% | 7% | 4.76% | 4.06% | 3.36% | 5.42% | 2.54% | 2.09% |
Acquisitions | -293.79M | -46.28M | -289.49M | 1.91M | -225.91M | 0 | -83.36M | -169.71M | -15M | 4.62M |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -36.99M | 680K | -21.9M | 0 | 0 | -53M | -232M | 7M | 15.26M | 5.3M |
Cash from Financing | 189.39M | -99.19M | 134.38M | -183.8M | -62.55M | -242.85M | 22.62M | -122.4M | -253.91M | -226.36M |
Debt Issued (Net) | 252M | -4.5M | 166.5M | -148.5M | -15.5M | -85.5M | 94M | -31M | 27M | -130M |
Equity Issued (Net) | 0 | 0 | -15.4M | -50.11M | -43.18M | -160.95M | -19.56M | -80.04M | -275.73M | -65.38M |
Dividends Paid | -47.33M | -47.97M | -48.36M | -48.9M | -49.62M | -50.19M | -50.28M | -50.42M | -50.39M | -49.82M |
Share Repurchases | 0 | 0 | -15.4M | -50.11M | -43.18M | -160.95M | -19.56M | -80.04M | -275.73M | -100.08M |
Other Financing | -15.56M | -46.72M | 31.65M | 63.71M | 45.75M | 53.78M | -1.54M | 39.06M | 45.22M | 18.84M |
Net Change in Cash | 27.38M▲ 0% | 30.38M▲ 11.0% | -21.1M▼ 169.5% | 45.74M▲ 316.7% | 52.47M▲ 14.7% | -26.52M▼ 150.6% | 8M▲ 130.2% | -28.78M▼ 459.6% | 10.39M▲ 136.1% | 69.15M▲ 0% |
Free Cash Flow | 128.27M▲ 0% | 149.43M▲ 16.5% | 156.21M▲ 4.5% | 153.47M▼ 1.8% | 307.86M▲ 100.6% | 280.36M▼ 8.9% | 216.15M▼ 22.9% | 236.1M▲ 9.2% | 256.55M▲ 8.7% | 269.6M▲ 0% |
FCF Margin % | 22.78% | 23.24% | 21.88% | 20.78% | 33.07% | 25.36% | 19.02% | 20.37% | 21.04% | 22.27% |
FCF Growth % | 1.02% | 16.5% | 4.53% | -1.75% | 100.6% | -8.93% | -22.9% | 9.23% | 8.66% | 22.13% |
FCF per Share | 0.86 | 0.98 | 1.00 | 0.97 | 1.90 | 1.71 | 1.34 | 1.47 | 1.61 | 1.72 |
FCF Conversion (FCF/Net Income) | 1.86x | 1.36x | 1.89x | 0.89x | 2.51x | 1.20x | 0.89x | 1.78x | 3.92x | 2.46x |
Interest Paid | 7.45M | 9.84M | 21.5M | 18.61M | 13.58M | 11.03M | 8.37M | 14.5M | 18.95M | 9.54M |
Taxes Paid | 42.9M | 35.08M | 36.81M | 41.99M | 20.95M | 30.34M | 88.43M | 65.25M | 74.36M | -9.41M |
TECH Key Ratios
Bio-Techne Corporation (TECH) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 8.45% | 12.35% | 8.56% | 18.01% | 9.51% | 16.63% | 15.56% | 8.33% | 3.68% | 5.49% |
Return on Invested Capital (ROIC) | 8.47% | 8.15% | 6.57% | 7.29% | 10.29% | 12.2% | 10.95% | 6.77% | 3.38% | 5.26% |
Gross Margin | 66.53% | 67.21% | 66.31% | 65.41% | 67.97% | 68.42% | 67.72% | 66.41% | 64.8% | 64.96% |
Net Margin | 13.73% | 19.49% | 13.46% | 31.04% | 15.08% | 24.61% | 25.1% | 14.5% | 6.02% | 9.05% |
Debt / Equity | 0.37x | 0.31x | 0.43x | 0.31x | 0.27x | 0.19x | 0.23x | 0.20x | 0.23x | 0.14x |
Interest Coverage | 16.21x | 13.36x | 6.16x | 15.40x | 11.62x | 27.65x | 31.20x | 12.80x | 12.57x | 15.11x |
FCF Conversion | 1.86x | 1.36x | 1.89x | 0.89x | 2.51x | 1.20x | 0.89x | 1.78x | 3.92x | 2.46x |
Revenue Growth | 12.82% | 14.21% | 11.04% | 3.46% | 26.04% | 18.75% | 2.81% | 1.97% | 5.23% | 0.17% |
Related:TECH Dividend History·TECH Revenue History·TECH Price History·TECH P/E History·TECH Financial Ratios·TECH Institutional Holders
TECH SEC Filings & Documents
Bio-Techne Corporation (TECH) SEC filings — annual & quarterly reports (10-K, 10-Q)
TECH Frequently Asked Questions
Bio-Techne Corporation (TECH) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Bio-Techne Corporation (TECH) reported $1.21B in revenue for fiscal year 2025. This represents a 2118% increase from $54.6M in 1996.
Bio-Techne Corporation (TECH) grew revenue by 5.2% over the past year. This is steady growth.
Yes, Bio-Techne Corporation (TECH) is profitable, generating $109.6M in net income for fiscal year 2025 (6.0% net margin).
Dividend & Returns
Yes, Bio-Techne Corporation (TECH) pays a dividend with a yield of 0.54%. This makes it attractive for income-focused investors.
Bio-Techne Corporation (TECH) has a return on equity (ROE) of 3.7%. This is below average, suggesting room for improvement.
Bio-Techne Corporation (TECH) generated $269.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.